

VIAMET PHARMACEUTICALS TO PRESENT AT THE 32nd Annual J.P. MORGAN HEALTHCARE CONFERENCE

CEO Robert Schotzinger to provide an update on Viamet's prostate cancer and antifungal clinical programs.

January 8, 2014, Research Triangle Park, North Carolina – [Viamet Pharmaceuticals, Inc.](#), a world leader in the development of best-in-class therapies targeting metalloenzymes, announced today that Robert Schotzinger, M.D., Ph.D., President and CEO of Viamet, will present an overview of the Company at the 32nd Annual J.P. Morgan Healthcare Conference in San Francisco on Tuesday, January 14, beginning at 8:00 a.m. Pacific Time. The presentation will be held in the Elizabethan C Ballroom at the Westin St. Francis Hotel.

“We achieved significant clinical progress with our lead prostate cancer compound, VT-464, and our lead antifungal compound, VT-1161, during 2013,” said Dr. Schotzinger. “It is an honor to be invited by J.P. Morgan to provide an update on our programs and to discuss our clinical plans for the coming year.”

About VT-464

VT-464 is an oral, small molecule inhibitor of the bifunctional metalloenzyme, CYP17. VT-464 is entering Phase 2 clinical development for the treatment of castration-resistant prostate cancer. Viamet utilized the Company's proprietary Metallophile™ technology platform to design VT-464 to be a lyase-selective inhibitor of CYP17. Due to its high lyase selectivity, VT-464 is administered without concomitant prednisone, unlike the approved CYP17 inhibitor, Zytiga™. Recent preclinical studies have demonstrated robust VT-464 activity in prostate tumor models that are resistant to Zytiga™ or the androgen receptor blocker, Xtandi™. A Phase 1/2 clinical trial of VT-464 in chemotherapy-naïve, castration-resistant prostate cancer patients is currently ongoing. Additional clinical trials are planned for early 2014 in patients who have previously failed approved therapies including Zytiga™, Xtandi™ and chemotherapy.

About VT-1161

VT-1161 is an oral, small molecule inhibitor of the fungal metalloenzyme, CYP51. VT-1161 is in Phase 2 clinical development for the treatment of a range of human fungal infections. Viamet utilized its proprietary Metallophile™ technology platform to design VT-1161 to be highly selective for the fungal CYP51 enzyme, while sparing human CYP enzymes with the goal of reducing the significant toxicities observed with CYP51 inhibitors currently on market. VT-1161 has shown robust activity in multiple preclinical models of superficial, mucosal, and invasive fungal infections. Oral VT-1161 demonstrated excellent safety, pharmacokinetics and penetration into human skin and nail in Phase 1 studies. Phase 2a studies of oral VT-1161 are currently ongoing in patients with interdigital tinea pedis and in patients with acute vulvovaginal candidiasis. Pending the successful completion of these studies, the Company expects to initiate Phase 2b trials of oral VT-1161 in patients with onychomycosis and recurrent vulvovaginal candidiasis.

About the Viamet Group of Companies (www.viamet.com)

Viamet develops best-in-class inhibitors of metalloenzymes that were discovered using its proprietary platform, the Metallophile™ Technology. The Metallophile™ Technology evolved from the Company's world-class expertise in bioinorganic chemistry and its extensive insights into metalloenzyme structure and function. The Metallophile™ Technology has enabled Viamet to rapidly build a portfolio of proprietary clinical-stage compounds and drug candidates that address significant unmet medical needs and represent significant commercial potential.



Contact:

Rich Katz, M.D., Chief Business and Financial Officer
Viamet Pharmaceuticals, Inc.
4505 Emperor Boulevard, Suite 300
Durham, North Carolina, USA 27703
Telephone: +919.467.8539 ext. 316

This press release includes forward-looking statements. Actual results may vary materially from these statements. There are many important risks affecting Viamet's business and VT-464 and VT-1161, including that clinical trials may not be successful, regulatory approvals may not be obtained and approved products, if any, may not achieve commercial success.

The Viamet group of companies includes Viamet Pharmaceuticals Holdings, LLC and its operating subsidiaries, Viamet Pharmaceuticals, Inc., VPS-1, Inc., VPS-2, Inc. and VPS-3, Inc. The Viamet group of companies is based in the Research Triangle Park region of North Carolina, USA.